The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...
This was the stock's third consecutive day of losses.
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
While Regeneron records net product sales of Eylea in the United States, Bayer does the same outside the United States. The company also records its share of profits/losses in connection with ...
Two biotech companies failed to reverse orders barring them from selling biosimilars of Regeneron’s eye disease drug Eylea in rulings from a federal appeals court … ...
Veru's experimental drug helps older obese patients on Wegovy preserve muscle January 27, 2025 Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 ...
The company has amassed 150 staff to sell Journavx, which it priced at $15.50 per pill, or about $30 per day. Cost and patient access are concerns with most new medicines, but they can be especially ...
Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...
It's a web-based service that can auto-generate logos. All you need to do is add your company's name, as well as provide information on what sort of business you offer, as well as picking a few ...
Then, on October 31, 2024, Regeneron announced financial results for Q3 2024 that included disappointing U.S. net sales for its EYLEA and EYLEA HD products. The company revealed that those sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
